Lobbying Filing Details

Total Spending

$90,000

Activities

5

Lobbyists

3

Gov't Entities

12

Filing Information
Filing UUID:
cd957248-35fe-4fc7-822e-ebb4eb8b94b8
Type:
Q2 - 2nd Quarter - Report
Period:
2023 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 10, 2023 at 2:03 PM
Income:
$90,000
Expenses:
$0
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Jennifer Leib
Registrant
IPOLICY SOLUTIONS

Government Affairs Consulting firm

Washington, District of Columbia
Client
INVITAE INC.

Company that provides clinical genetic testing services.

California, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

No bill #: FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill H.R.4366/S.2127: FY2024 Military Construction, Veterans Affairs, and Related Agencies Appropriations bill H.R.2670: National Defense Authorization Act for FY24

Lobbyists (3)
  • JENNIFER RACHEL LEIB
  • MEGAN ANDERSON BROOKS
  • LINDSEY TRISCHLER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Copyright/Patent/Trademark

S.2140: Patent Eligibility Restoration Act

Lobbyists (3)
  • JENNIFER RACHEL LEIB
  • MEGAN ANDERSON BROOKS
  • LINDSEY TRISCHLER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Health Issues

No bill #: Right Drug Dose Now Act H.R.4189/S.2016: CONNECT for Health Act No bill #: Pharmacogenomics Education and Research Act RIN 0945-AA20, HIPAA Privacy Rule to Support Reproductive Health Care Privacy

Lobbyists (3)
  • JENNIFER RACHEL LEIB
  • MEGAN ANDERSON BROOKS
  • LINDSEY TRISCHLER
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Health & Human Services, Dept of (HHS)
Activity 4
Medical/Disease Research/Clinical Labs

H.R.2369 - VALID Act of 2023 FDA Guidance, Docket No. FDA-2022-D-2983 for Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products FDA public meeting, FDA-2018-N-4002 Electronic Submission of Adverse Event Reports to FAERS Using ICH E2B(R3) Standards FDA guidance, Docket No. FDA-2023-D-0110: Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics

Lobbyists (3)
  • JENNIFER RACHEL LEIB
  • MEGAN ANDERSON BROOKS
  • LINDSEY TRISCHLER
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Food & Drug Administration (FDA)
Activity 5
Medicare/Medicaid

No bill #: Precision Medicine Access for Kids Today Act

Lobbyists (3)
  • JENNIFER RACHEL LEIB
  • MEGAN ANDERSON BROOKS
  • LINDSEY TRISCHLER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.